484 related articles for article (PubMed ID: 25484261)
1. HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma.
Wang H; Zhang Z; Sun R; Lin H; Gong L; Fang M; Hu WH
J Voice; 2015 May; 29(3):356-62. PubMed ID: 25484261
[TBL] [Abstract][Full Text] [Related]
2. Prostate tumor overexpressed-1, in conjunction with human papillomavirus status, predicts outcome in early-stage human laryngeal squamous cell carcinoma.
Yang L; Wang H; Wang Y; He Z; Chen H; Liang S; He S; Wu S; Song L; Chen Y
Oncotarget; 2016 May; 7(22):31878-91. PubMed ID: 26992242
[TBL] [Abstract][Full Text] [Related]
3. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.
Young RJ; Urban D; Angel C; Corry J; Lyons B; Vallance N; Kleid S; Iseli TA; Solomon B; Rischin D
Br J Cancer; 2015 Mar; 112(6):1098-104. PubMed ID: 25688737
[TBL] [Abstract][Full Text] [Related]
4. HPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancers.
Kanyilmaz G; Ekinci O; Muge A; Celik S; Ozturk F
Asian Pac J Cancer Prev; 2015; 16(1):253-8. PubMed ID: 25640361
[TBL] [Abstract][Full Text] [Related]
5. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
6. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.
Mooren JJ; Gültekin SE; Straetmans JM; Haesevoets A; Peutz-Kootstra CJ; Huebbers CU; Dienes HP; Wieland U; Ramaekers FC; Kremer B; Speel EJ; Klussmann JP
Int J Cancer; 2014 May; 134(9):2108-17. PubMed ID: 24127203
[TBL] [Abstract][Full Text] [Related]
7. Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO
Hoffmann M; Quabius ES; Tribius S; Gebhardt S; Görögh T; Hedderich J; Huber K; Dunst J; Ambrosch P
Cancer Lett; 2018 Jan; 413():59-68. PubMed ID: 29100961
[TBL] [Abstract][Full Text] [Related]
8. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
9. P16(INK⁴a) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas.
Larque AB; Conde L; Hakim S; Alos L; Jares P; Vilaseca I; Cardesa A; Nadal A
Virchows Arch; 2015 Apr; 466(4):375-82. PubMed ID: 25652585
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.
Fakhry C; Westra WH; Wang SJ; van Zante A; Zhang Y; Rettig E; Yin LX; Ryan WR; Ha PK; Wentz A; Koch W; Richmon JD; Eisele DW; D'Souza G
Cancer; 2017 May; 123(9):1566-1575. PubMed ID: 28241096
[TBL] [Abstract][Full Text] [Related]
11. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
Sznurkowski JJ; Żawrocki A; Biernat W
BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma.
Deng Z; Hasegawa M; Aoki K; Matayoshi S; Kiyuna A; Yamashita Y; Uehara T; Agena S; Maeda H; Xie M; Suzuki M
Int J Oncol; 2014 Jul; 45(1):67-76. PubMed ID: 24820457
[TBL] [Abstract][Full Text] [Related]
13. Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas.
Dahm V; Haitel A; Kaider A; Stanisz I; Beer A; Lill C
Eur Arch Otorhinolaryngol; 2018 Jul; 275(7):1837-1843. PubMed ID: 29744637
[TBL] [Abstract][Full Text] [Related]
14. P16INK4a expression, human papillomavirus, and survival in head and neck cancer.
Smith EM; Wang D; Kim Y; Rubenstein LM; Lee JH; Haugen TH; Turek LP
Oral Oncol; 2008 Feb; 44(2):133-42. PubMed ID: 17360226
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of human papilloma virus on survival of basaloid squamous carcinoma of the head and neck.
Jacobi C; Ayx I; Fritsche K; Piontek G; Hoffmann D; Weirich G; Knopf A
Oncotarget; 2015 Feb; 6(5):3462-70. PubMed ID: 25739121
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.
Gheit T; Abedi-Ardekani B; Carreira C; Missad CG; Tommasino M; Torrente MC
J Med Virol; 2014 Apr; 86(4):642-6. PubMed ID: 24374907
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma.
Gröbe A; Hanken H; Kluwe L; Schöllchen M; Tribius S; Pohlenz P; Clauditz T; Grob T; Simon R; Sauter G; Heiland M; Blessmann M
J Oral Pathol Med; 2013 Oct; 42(9):676-81. PubMed ID: 23721566
[TBL] [Abstract][Full Text] [Related]
18. Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus.
Mehrad M; Carpenter DH; Chernock RD; Wang H; Ma XJ; Luo Y; Luo J; Lewis JS; El-Mofty SK
Am J Surg Pathol; 2013 Sep; 37(9):1349-56. PubMed ID: 23797720
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
20. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
